Curasan AG

euro adhoc: quarterly or semiannual financial statement
curasan: First quarterly break-even result

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.

quaterly report


Kleinostheim, 25 April 2008 - curasan AG (ISIN: DE 000 549 453 8) has succeeded in increasing its revenues of Q1/2008 by 13% compared to Q1/2007 from 2.6 million Euro to 2.9 million Euro. Due to its concurrent cost reduction the company achieved a break-even in the quarterly revenue result for the first time.

The full Q1/2008 report will be published on May 13, 2008.

About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. With the REVOIS® implant system, the company´s sales is focusing more prominently on the growth market of dental surgery/implantology. The majority of new products emerging from the substantial development pipeline are to be offered under licence within other medical fields. Please visit curasan´s corporate website at

end of announcement                               euro adhoc

Further inquiry note:

Dr. Erwin Amashaufer, curasan AG, Tel. +49 6027/46 86-465, email:

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade

Original-Content von: Curasan AG, übermittelt durch news aktuell

Weitere Meldungen: Curasan AG

Das könnte Sie auch interessieren: